Multiple sclerosis (MS) is a demyelinating disease of unknown etiology that affects the Central Nervous System (CNS) where autoimmune-mediated mechanisms are thought to be at work. There are two possible options for treating MS, to prevent damage, and to repair the already impaired CNS. Stem Cells (SC) therapy emerges as a potential new hope for MS patients as it could accomplish both functions. There is a growing body of literature that supports the potential of the SC for immunomodulation and re-myelination. Here we focus on examining the registered published and on-going clinical trials using the Mesenchymal Stem Cell (MSC) therapy in MS. We have found that a total of 85 patients were enrolled in 9 cell-base studies with encouraging results. These studies were not statistically analyzed; however, they showed safety of the MSC therapy. Based on the results emerging from these patients, who failed to respond to even immunosuppressive drugs, clinical improvement was observed in 62%, a stable course in 22%; and 16% remaining in a progressive course. Given the evidence, we support that cell-based therapies are safe and reasonable to initiate a double blind, randomized controlled trials. This would represent a new and unique therapeutic approach for the progressive forms of MS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.